Diary - News
All news PDC*line Pharma obtains authorization to launch phase I/II...
PDC*line is a potent, scalable and versatile professional antigenpresenting T-cell with great potential for treating a range of cancers.
PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today that the Belgian Federal Agency for
Medicines Health Product (FAMHP), together with the designated Ethics Committee, have authorized the initiation of an open-label, dose-escalation, phase I/II trial with its cancer vaccine candidate (PDC*lung01) for non-small-cell lung cancer (NSCLC).
By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Service. More information... Close